SLP
Fiscal year ends August Quarters are offset from the calendar — Q1 is Sep–Nov

Simulations Plus, Inc. is a provider of modeling and simulation software and consulting services for the biopharmaceutical sector. The company supports drug discovery, development, clinical trial operations, and commercialization through model-informed drug development solutions. Its software portfolio includes ADMET Predictor for AI-driven property prediction, GastroPlus for physiologically based pharmacokinetics, and MonolixSuite for population modeling. The company also offers specialized tools such as DILIsym for liver injury prediction and Pro-ficiency for clinical trial compliance training. Simulations Plus serves major pharmaceutical, biotechnology, agrochemical, and cosmetics companies, as well as academic and regulatory agencies worldwide. Founded in 1996, the company integrates artificial intelligence and machine learning with mechanistic models to optimize drug development timelines and reduce costs.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Software - Application Homepage simulations-plus.com
Sector Technology IR page —
Tags
pharmacokinetics, drug discovery, clinical trial simulation, artificial intelligence, machine learning, toxicology, biosimulation, regulatory compliance, quantitative systems pharmacology, ADMET Predictor, MedChem Designer, GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales, MonolixSuite, Monolix, PKanalix, Simulx, Pro-ficiency, Panorama KOL Insights, ADMET Modeler
Press page —

Metrics

Valuation  
Market cap $ 369.556M
Market cap (USD) —
P/E 25.39
PEG —
P/BV 2.66
P/S —
P/OCF 14.82
P/FCF 15.06
Dividend yield 0.05%
Turnover / mcap —
Returns  
ROE -42.1%
ROI -68.6%
ROIC -56.2%
Profit margin -81.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2009 FY 2008
Revenue 79.179M 70.013M 59.577M 53.906M 46.466M 41.589M 33.97M 29.667M 24.138M 19.972M 18.314M 11.461M 10.071K 9.449K 9.143M 8.968M
Net profit -64.718M 9.954M 9.961M 12.483M 9.782M 9.332M 8.583M 8.935M 5.788M 4.95M 3.843M 3.025M 2.887M 3.028M 1.412M 1.726M
Free cash flow 17.413M 12.754M 21.403M 17.081M 17.576M 10.681M 11.501M 9.104M 6.702M 5.376M 7.064M 5.282M 2.509M 3.677M 2.447M 2.395M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2009 FY 2008
Share price 14.1 35.59 49.29 60.65 44.33 58.16 36.22 20.33 15.07 7.56 6.27 5.62 4.17 — 1.63 1.61
Price performance 12m -0.6 -0.28 -0.19 0.37 -0.24 0.61 0.78 0.35 0.99 0.21 0.12 0.35 — — 0.01 -0.84

Filed figures

Figure Aug 2016 Aug 2017 Aug 2018 Aug 2019 Aug 2020 Aug 2021 Aug 2022 Aug 2023 Aug 2024 Aug 2025
Balance sheet detail
Trade receivables (USD) 3.01M 4.05M 5.51M 5.03M 7.42M 9.85M 13.8M 10.2M 9.14M 9.72M
↳ YoY growth +88.8% +34.5% +36.2% -8.8% +47.7% +32.7% +40.0% -26.0% -10.4% +6.4%
↳ 5y CAGR +20.8% +22.8% +23.6% +24.1% +36.0% +26.8% +27.8% +13.1% +12.7% +5.5%
Borrowings, current (USD) — 247,328 2.56M — — — — — — —
Lease liabilities (USD) — — — 0.00 926,777 1.28M 1.4M 1.2M 1.01M 616,000
Cash and deposits (USD) 8.03M 6.22M 9.4M 11.4M 49.2M 37M 51.6M 57.5M 10.3M 30.9M
Intangible assets (USD) 4.67M 6.83M 5.91M 5.03M 11.9M 10.5M — — — —
Right-of-use assets (USD) — — — 0.00 926,600 1.28M 1.42M 1.25M 1.03M 407,000
Net debt (borrowings + leases - cash) (USD) — -5.97M -6.84M — — — — — — —
Cash flow detail
Operating cash flow (USD) 5.42M 6.88M 9.29M 11.6M 10.9M 19.2M 17.9M 21.9M 13.3M 18.1M
Purchases of property, plant and equipment (USD) -39,121 -175,961 -183,291 -137,745 -231,380 -1.63M -819,000 -453,000 -566,000 -713,000
Purchases of intangible assets (USD) — 0.00 0.00 -50,000 0.00 0.00 — — — —
Change in receivables (cash effect) (USD) -1.42M -876,231 -1.47M 487,970 -2.02M -2.43M -3.94M 4.1M 3.13M -581,000
Change in payables (cash effect) (USD) -101,296 99,337 110,713 -147,529 220,584 39,000 -162,000 -81,000 -477,000 -132,000
Dividends paid (cash effect) (USD) -3.41M -3.45M -4.16M -4.2M -4.25M -4.81M -4.85M -4.81M -4.8M 0.00
Share buybacks (cash effect) (USD) — — — — — 0.00 0.00 -20M 0.00 0.00
Income taxes paid (cash effect) (USD) -2.91M -2.69M -2.71M -2.67M -2.35M -1.86M -3.23M -3.2M -5.69M -1.16M
Share-based compensation (USD) 347,077 585,018 709,083 1.08M 1.58M 2.75M 3.04M 4.83M 6.54M 6.35M
Operating cash flow before change in receivables (USD) 6.83M 7.75M 10.8M 11.2M 12.9M 21.6M 21.8M 17.8M 10.2M 18.7M
Free cash flow (OCF - PPE - intangibles) (USD) 5.38M 6.7M 9.1M 11.5M 10.7M 17.6M 17.1M 21.4M 12.8M 17.4M
Income detail
Research and development expense (USD) 1.45M 1.37M 1.79M 2.5M 2.97M 4.05M 3.21M 4.5M 5.75M 6.88M
↳ 5y CAGR +9.1% +7.6% +17.4% +21.3% +17.5% +22.9% +18.6% +20.3% +18.1% +18.3%
Total comprehensive income (USD) — — 0.00 0.00 9.39M 9.68M 12.2M 10.1M 9.84M -64.7M
Comprehensive income to owners (USD) — — 0.00 0.00 9.39M 9.68M 12.2M 10.1M 9.84M -64.7M
Provision for credit losses (USD) — — — — — 28,000 -66,000 77,000 189,000 95,000
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.3% 0.6% 0.6% 2.0% 1.0%
Reported Nov 14, 2016 Nov 13, 2019 Nov 16, 2020 Nov 16, 2020 Nov 16, 2020 Oct 27, 2023 Oct 27, 2023 Oct 27, 2023 Oct 30, 2024 Dec 1, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Authors: de la Cruz Cruz P , Gomide LLR , do Nascimento GM , Urizar JTP , Muñoz AM , Guillén AdJP , Reyes HEF , Ramírez RZ , Cruz LMR , Sánchez MG , García MA , Issa MG , Duque MD

Publication: AAPS J

Keywords: Amlodipine , BCS Class III , bioequivalence , biowaivers , dissolution modeling , Dissolution Risk Assessment , gastroplus , Immediate-Release Tablets , In Vitro–In Vivo Relationships , membraneplus , oral drug absorption , pbbm , pharmacokinetics , physiologically based biopharmaceutics modeling , virtual bioequivalence

Software: GastroPlus®

Abstract

A conservative BCS class III classification was recently proposed for amlodipine based on inconclusive permeability evidence. However, the scarce in vivo data suggest that amlodipine is slowly, though completely, absorbed. This means that the very rapid dissolution criterion associated with a BCS class III classification may be overly restrictive for immediate-release amlodipine products. The aim of this manuscript was to develop and validate a physiologically based biopharmaceutics model (PBBM) to assess the risk of bioequivalence failure associated with dissolution. Given that amlodipine is a lipophilic weak base, the absorption model incorporated a surrogate representation of intracellular lysosomal trapping through the FuEnt parameter, resulting in an adequate description of oral pharmacokinetics. Dissolution input included in vitro profiles obtained in phosphate buffer pH 6.8 at 50 rpm for different multisource products, fitted to either the Johnson model or the Z-factor approach. Although several products did not meet biowaiver dissolution criteria, virtual bioequivalence simulations conducted with the validated PBBM consistently predicted bioequivalence across tested formulations. Overall, these findings suggest that dissolution differences would have limited impact on the in vivo performance of amlodipine and support a low dissolution-related bioequivalence risk for immediate-release amlodipine tablets.

By Porfirio de la Cruz Cruz, Larissa Lopes Rodrigues Gomide, Gabriela Moraes do Nascimento, José Trinidad Pérez Urizar, Alberto Martínez Muñoz, Ángel Antonio Vértiz Hernández, Amaury de Jesús Pozos Guillén, Héctor Eduardo Flores Reyes, Ricardo Zamora Ramírez, Luis Manuel Romero Cruz, Marcelino García Sánchez, Mauricio A. García, Michele Georges Issa & Marcelo Dutra Duque

Contact Us

*

First Name:

*

Last Name:

*

Company:

*

Job Title

*

Country

Select...United StatesAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaArgentinaAntigua and BarbudaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongo (Republic)Congo (Democratic Republic)Cook IslandsCosta RicaCote dlvoireCroatiaCubaCuracaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland Islands (the) [Malvinas]Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuamGuatemalaGuadeloupeGuernseyGuineaGuinea-BissauGuyanaHeard Island and McDonald IslandsHaitiHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMacedoniaMadagascarMalawiMalaysiaMaldivesMacaoMaliMaltaMarshall IslandsMauritaniaMartiniqueMayotteMauritiusMexicoMicronesia (Federated States of)Moldova (the Republic of)MonacoMontserratMongoliaMontenegroMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRepublic of SerbiaRéunionRomaniaRussiaRwandaSaint BarthélemySaint LuciaSaint Helena, Ascension and Tristan da CunhaSaint Martin (French part)Saint Kitts and NevisSaint Pierre and MiquelonSaint Vincent and the GrenadinesSan MarinoSao Tome and PrincipeSamoaSaudi ArabiaSenegalSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSouth AfricaSouth Georgia and the South Sandwich IslandsSouth KoreaSomaliaSouth SudanSpainSri LankaSurinameSwedenSwitzerlandSyrian Arab RepublicSudanSvalbard and Jan MayenTaiwanTajikistanTanzaniaThailandTimor-LesteTokelauTongaTogoTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands (U.S.)Virgin Islands (British)Wallis and FutunaWestern SaharaYemenZambiaZimbabwe

*

Email

*

Industry:

Select...PharmaceuticalConsumer GoodsChemical/EnvironmentCannabis/TobaccoVeterinary MedicineAcademicNonprofitGovernment/AgencyOther

*

Interested In:

Select...ADMET PredictorConsulting ServicesComposerDDDPlusDILIsymGastroPlusILDsymIPFsymMembranePlusOBESITYsymMonolixNAFLDsymOtherPKanalixRENAsymSimulxPro-ficiency Performance ManagementPanorama KOL Insights Engine

This site is protected by reCAPTCHA.

Submit

Ready to get started?

Sign-up for a free evaluation or schedule a meeting with one of our experts!

Questions? Email [email protected]

Discuss my project needs with an expert

Schedule a software demo

Join our newsletter

Software

Services

Resources

About

Simulations Plus

Simulations Plus has been acquired by Altaris, LLC, a healthcare-focused investment firm. Read the press release to learn more.

×

This website uses cookies

We use cookies to enhance your browsing experience and analyze our traffic. To learn more about our use of cookies and other tracking technologies, please see our Cookie Notice and our Privacy Notice . By clicking “Accept All,” you consent to such use by us of cookies and other tracking technologies. To learn more about your privacy rights and our personal data practices, please see our Privacy Notice .

Accept All Reject AllCookie Settings

Manage consent

Close

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. For more information on use of cookies or similar tracking technologies on our website: View our Cookie Notice. Out of these, the cookies that are categorize...

Necessary

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie Duration Description
cookielawinfo-checkbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy 11 months The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Save & Accept

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can substantially reduce the time required to build and evaluate QSP models, supporting far broader use within model-informed drug development (MIDD) workflows.

QSP development has traditionally required scientists to make a series of choices about which biological mechanisms to include, how to structure the equations, and which parameters to optimize. These decisions are made with limited ability to test against plausible alternatives, but Turin is designed to change that. The engine enables systematic exploration and evaluation of candidate mechanistic structures against the available evidence in parallel, helping scientists identify the ones that best balance biological complexity, explanatory performance, and practical utility. Turin’s capabilities are further enhanced by the technical collaboration with NVIDIA that was announced in May 2026.

Under this collaboration, the pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists, who will provide scientific guidance throughout model evaluation. The approach combines AI-scale computational exploration with expert human scientific judgment, keeping the partner’s scientists directly engaged in every step of the QSP model-building and evaluation process. The partnership is intended to rapidly expand into more therapeutic development programs.

“QSP can provide powerful insight into complex biological systems, but the time and expertise required to build and evaluate these models has historically limited where and when they can be applied,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Turin is designed to break down that barrier and make QSP practical for a broader range of development decisions. Working alongside a leading pharmaceutical organization allows us to tailor this approach to meaningful challenges in a real-world development setting while continuing to advance the scientific capabilities of the engine.”

Organizations interested in learning more about Turin or exploring potential partnerships may contact Simulations Plus: https://www.simulations-plus.com/contact/

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com .

Forward-Looking Statements

Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance, regulatory compliance and commercialization of AI-enabled and cloud-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission. No regulatory authority has endorsed, approved, or validated the Company’s products, platforms, or AI-related approaches.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008831077/en/

**Media Contact:
**Christina Hendrickson
[email protected]

Simulations Plus Announces Completion of Acquisition by Altaris

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.

The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.

As previously announced, in connection with closing, Simulations Plus is being combined with Chemical Computing Group ("CCG"), an Altaris portfolio company and leading provider of molecular modeling and drug discovery software. Together, the organizations will create a broader platform spanning drug discovery, modeling, simulation, and development, enhancing their ability to serve customers across the pharmaceutical research and development lifecycle. Within the combined business, Simulations Plus will continue to operate under its own name and brand.

"Today marks an exciting new chapter for Simulations Plus," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Our mission has always been to help our customers accelerate the discovery, development, and commercialization of innovative therapies through advanced modeling, simulation, and AI-driven technologies. By joining CCG, we believe we are well positioned to accelerate investment in innovation, expand our capabilities, and expand the solution we provide to customers across the biopharmaceutical ecosystem. We want to thank our employees, customers, partners, and shareholders for their support throughout our journey as a public company."

"We are delighted to welcome the Simulations Plus team to CCG," said Paul Labute, Chief Executive Officer at CCG. "Simulations Plus has established itself as a trusted leader in biosimulation and model-informed drug development, supported by its science, differentiated technology, and deep customer relationships. We look forward to partnering with the company's talented team to support continued growth and innovation while advancing solutions that help improve the efficiency and success of drug development."

The combined organization will leverage the complementary technologies, scientific expertise, and customer relationships of both companies to accelerate innovation and provide an expanded suite of software and services supporting biopharmaceutical research and development.

About Simulations Plus, Inc.

Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com .

About Altaris

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20261006258966/en/

Media Contact:
Lisa Fortuna
Financial Profiles
310-622-8251
[email protected]

Prompts

Simulations Plus, Inc. (ticker SLP), listed in United States.

ETFs Holding Simulations Plus, Inc.

ETF Weight in ETF Shares Market value As of
RESM 0.01% 29 $ 530.99 Jun 30, 2026